These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 32009658)

  • 1. Isolation and Characterization of Patient-derived Pancreatic Ductal Adenocarcinoma Organoid Models.
    Tiriac H; French R; Lowy AM
    J Vis Exp; 2020 Jan; (155):. PubMed ID: 32009658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation and Culture of Tumor and Metastatic Organoids from Murine Models of Pancreatic Ductal Adenocarcinoma.
    Baker LA; Tuveson DA
    Methods Mol Biol; 2019; 1882():117-133. PubMed ID: 30378048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Establishment of organoid models for pancreatic ductal adenocarcinoma and screening of individualized therapy strategy.
    Gong M; Meng H; Tan D; Li P; Qin J; An Q; Shi C; An J
    Animal Model Exp Med; 2023 Oct; 6(5):409-418. PubMed ID: 37890865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical Modelling of PDA: Is Organoid the New Black?
    D'Agosto S; Andreani S; Scarpa A; Corbo V
    Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31195689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation and Culture of Human Pancreatic Ductal Adenocarcinoma Organoids from Resected Tumor Specimens.
    Baker LA; Tiriac H; Tuveson DA
    Methods Mol Biol; 2019; 1882():97-115. PubMed ID: 30378047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer-initiating cells in human pancreatic cancer organoids are maintained by interactions with endothelial cells.
    Choi JI; Jang SI; Hong J; Kim CH; Kwon SS; Park JS; Lim JB
    Cancer Lett; 2021 Feb; 498():42-53. PubMed ID: 33188841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pancreatic cancer-derived organoids - a disease modeling tool to predict drug response.
    Frappart PO; Walter K; Gout J; Beutel AK; Morawe M; Arnold F; Breunig M; Barth TF; Marienfeld R; Schulte L; Ettrich T; Hackert T; Svinarenko M; Rösler R; Wiese S; Wiese H; Perkhofer L; Müller M; Lechel A; Sainz B; Hermann PC; Seufferlein T; Kleger A
    United European Gastroenterol J; 2020 Jun; 8(5):594-606. PubMed ID: 32213029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modelling of pancreatic cancer biology: transcriptomic signature for 3D PDX-derived organoids and primary cell line organoid development.
    Nelson SR; Zhang C; Roche S; O'Neill F; Swan N; Luo Y; Larkin A; Crown J; Walsh N
    Sci Rep; 2020 Feb; 10(1):2778. PubMed ID: 32066753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Organoid models for translational pancreatic cancer research.
    Tiriac H; Plenker D; Baker LA; Tuveson DA
    Curr Opin Genet Dev; 2019 Feb; 54():7-11. PubMed ID: 30844513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Magnetic Fluid Hyperthermia as Treatment Option for Pancreatic Cancer Cells and Pancreatic Cancer Organoids.
    Palzer J; Mues B; Goerg R; Aberle M; Rensen SS; Olde Damink SWM; Vaes RDW; Cramer T; Schmitz-Rode T; Neumann UP; Slabu I; Roeth AA
    Int J Nanomedicine; 2021; 16():2965-2981. PubMed ID: 33935496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Organoid models of human and mouse ductal pancreatic cancer.
    Boj SF; Hwang CI; Baker LA; Chio II; Engle DD; Corbo V; Jager M; Ponz-Sarvise M; Tiriac H; Spector MS; Gracanin A; Oni T; Yu KH; van Boxtel R; Huch M; Rivera KD; Wilson JP; Feigin ME; Öhlund D; Handly-Santana A; Ardito-Abraham CM; Ludwig M; Elyada E; Alagesan B; Biffi G; Yordanov GN; Delcuze B; Creighton B; Wright K; Park Y; Morsink FH; Molenaar IQ; Borel Rinkes IH; Cuppen E; Hao Y; Jin Y; Nijman IJ; Iacobuzio-Donahue C; Leach SD; Pappin DJ; Hammell M; Klimstra DS; Basturk O; Hruban RH; Offerhaus GJ; Vries RG; Clevers H; Tuveson DA
    Cell; 2015 Jan; 160(1-2):324-38. PubMed ID: 25557080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PDX-derived organoids model in vivo drug response and secrete biomarkers.
    Huang L; Bockorny B; Paul I; Akshinthala D; Frappart PO; Gandarilla O; Bose A; Sanchez-Gonzalez V; Rouse EE; Lehoux SD; Pandell N; Lim CM; Clohessy JG; Grossman J; Gonzalez R; Del Pino SP; Daaboul G; Sawhney MS; Freedman SD; Kleger A; Cummings RD; Emili A; Muthuswamy LB; Hidalgo M; Muthuswamy SK
    JCI Insight; 2020 Nov; 5(21):. PubMed ID: 32990680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Organoids Models of Pancreatic Duct Adenocarcinoma.
    Yu C; Kang R; Tang D
    Methods Mol Biol; 2023; 2712():45-60. PubMed ID: 37578695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation between drug sensitivity profiles of circulating tumour cell-derived organoids and clinical treatment response in patients with pancreatic ductal adenocarcinoma.
    Wu YH; Hung YP; Chiu NC; Lee RC; Li CP; Chao Y; Shyr YM; Wang SE; Chen SC; Lin SH; Chen YH; Kang YM; Hsu SM; Yen SH; Wu JY; Lee KD; Tseng HE; Tsai JR; Tang JH; Chiou JF; Burnouf T; Chen YJ; Wang PY; Lu LS
    Eur J Cancer; 2022 May; 166():208-218. PubMed ID: 35306319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel methods for in vitro modeling of pancreatic cancer reveal important aspects for successful primary cell culture.
    Ehlen L; Arndt J; Treue D; Bischoff P; Loch FN; Hahn EM; Kotsch K; Klauschen F; Beyer K; Margonis GA; Kreis ME; Kamphues C
    BMC Cancer; 2020 May; 20(1):417. PubMed ID: 32404074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer.
    Grossman JE; Muthuswamy L; Huang L; Akshinthala D; Perea S; Gonzalez RS; Tsai LL; Cohen J; Bockorny B; Bullock AJ; Schlechter B; Peters MLB; Conahan C; Narasimhan S; Lim C; Davis RB; Besaw R; Sawhney MS; Pleskow D; Berzin TM; Smith M; Kent TS; Callery M; Muthuswamy SK; Hidalgo M
    Clin Cancer Res; 2022 Feb; 28(4):708-718. PubMed ID: 34789479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-Derived Organoid Pharmacotyping Guides Precision Medicine for Pancreatic Cancer.
    Zhang Y; Houchen CW; Li M
    Clin Cancer Res; 2022 Aug; 28(15):3176-3178. PubMed ID: 35617521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Precision Medicine in Pancreatic Cancer: Patient-Derived Organoid Pharmacotyping Is a Predictive Biomarker of Clinical Treatment Response.
    Seppälä TT; Zimmerman JW; Suri R; Zlomke H; Ivey GD; Szabolcs A; Shubert CR; Cameron JL; Burns WR; Lafaro KJ; He J; Wolfgang CL; Zou YS; Zheng L; Tuveson DA; Eshlemann JR; Ryan DP; Kimmelman AC; Hong TS; Ting DT; Jaffee EM; Burkhart RA
    Clin Cancer Res; 2022 Aug; 28(15):3296-3307. PubMed ID: 35363262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Basement membrane destruction by pancreatic stellate cells leads to local invasion in pancreatic ductal adenocarcinoma.
    Koikawa K; Ohuchida K; Ando Y; Kibe S; Nakayama H; Takesue S; Endo S; Abe T; Okumura T; Iwamoto C; Moriyama T; Nakata K; Miyasaka Y; Ohtsuka T; Nagai E; Mizumoto K; Hashizume M; Nakamura M
    Cancer Lett; 2018 Jul; 425():65-77. PubMed ID: 29580808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3D imaging analysis on an organoid-based platform guides personalized treatment in pancreatic ductal adenocarcinoma.
    Kang Y; Deng J; Ling J; Li X; Chiang YJ; Koay EJ; Wang H; Burks JK; Chiao PJ; Hurd MW; Bhutani MS; Lee JH; Weston BR; Maitra A; Ikoma N; Tzeng CD; Lee JE; DePinho RA; Wolff RA; Pant S; McAllister F; Katz MH; Fleming JB; Kim MP
    J Clin Invest; 2022 Dec; 132(24):. PubMed ID: 36282600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.